146 related articles for article (PubMed ID: 31882503)
1. Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.
Okauchi S; Sasatani Y; Ohara G; Kagohashi K; Satoh H
In Vivo; 2020; 34(1):389-392. PubMed ID: 31882503
[TBL] [Abstract][Full Text] [Related]
2. What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?
Remolina-Bonilla YA; Trejo-Rosales RR; Saldivar-Oviedo B; Gabutti A; Bourlon MT
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469900
[No Abstract] [Full Text] [Related]
3. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
5. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Ikeuchi N; Igata F; Kinoshita E; Kawabata T; Tan I; Osaki Y; Otsuka R; On R; Ikeda T; Nakao A; Sasaki T; Aoyama T; Hirano R; Harada T; Ebi N; Fujita M; Inoue H
Anticancer Res; 2023 Feb; 43(2):713-724. PubMed ID: 36697078
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
[No Abstract] [Full Text] [Related]
7. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
8. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
Yuan S; Hu X; Zhao Y; Wang Z
Front Immunol; 2020; 11():563622. PubMed ID: 33240259
[TBL] [Abstract][Full Text] [Related]
9. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Dhillon S; Syed YY
Target Oncol; 2019 Dec; 14(6):759-768. PubMed ID: 31728860
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
12. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
[TBL] [Abstract][Full Text] [Related]
13. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.
Egger EK; Ralser DJ; Lindner K; Recker F; Marinova M; Savchenko O; Lau JF; Mustea A
Front Immunol; 2021; 12():686879. PubMed ID: 34367146
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
[TBL] [Abstract][Full Text] [Related]
17. [A case of complete resection of non-squamous non-small-cell lung cancer after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab].
Kawaharada Y; Imai K; Minamiya Y; Saito H; Konno H; Fujishima S; Ogawa J
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1533-7. PubMed ID: 23064066
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Liu SV; Camidge DR; Gettinger SN; Giaccone G; Heist RS; Hodi FS; Ready NE; Zhang W; Wallin J; Funke R; Waterkamp D; Foster P; Iizuka K; Powderly J
Eur J Cancer; 2018 Sep; 101():114-122. PubMed ID: 30053670
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
